Rhode Island House Bill H8245

Rhode Island 2026 Regular Session

• Introduced: 3/6/26
• Refer: 3/6/26

Caption

Requires the state, and private insurers that cover prescription hormone therapy, to dispense twelve (12) months’ worth of the prescription as a single prescription.

Impact

The implementation of HB 8245 represents a significant change in the way hormone therapies are dispensed and covered by insurance in Rhode Island. By allowing a full year’s supply to be dispensed at once, the bill aims to alleviate patient burdens such as time and costs associated with multiple pharmacy visits. This policy initiative is designed to enhance the quality of care for individuals requiring hormone therapy and is expected to contribute positively to public health outcomes by ensuring patients adhere to their prescribed regimes. Furthermore, the bill would instruct the state's health insurance sector to adapt to a more patient-centered approach.

Summary

House Bill 8245, introduced in the Rhode Island General Assembly, focuses on improving access to prescription hormone therapy by mandating that health insurance plans provide patients with up to 365 days' worth of medication in a single prescription. Under this proposed legislation, beginning January 1, 2027, every health insurance contract, both individual and group plans, must comply with this reimbursement directive, allowing patients to manage their therapy more effectively without the need for frequent refills. The bill specifically excludes certain medications, like glucagon-like peptide-1, thereby streamlining the coverage process for hormone therapy.

Contention

Although the bill has potential benefits, it may face challenges regarding its legislative journey. Points of contention are likely to arise over the exclusions of certain drugs and the implications of drug utilization management strategies health plans may apply. Opponents might argue that the legislation could lead to higher costs for insurance companies and complications in managing controlled substances. Stakeholders outside the legislature, including health advocates and insurance representatives, will likely scrutinize the practical implications of this law, from its administrative feasibility to its overall impact on insurance premiums and availability of specific therapies.